Cancers, Vol. 16, Pages 1165: Exploratory Assessment of Galectin-1, -3, and -9 in Non-Small Cell Lung Cancer

Cancers, Vol. 16, Pages 1165: Exploratory Assessment of Galectin-1, -3, and -9 in Non-Small Cell Lung Cancer Cancers doi: 10.3390/cancers16061165 Authors: Hayden Shuster Avery Funkhouser Lorie Allen Moonseong Heo Julie C. Martin W. Jeffery Edenfield Anna V. Blenda Galectins play a pivotal role in lung cancer oncogenic pathways, influencing apoptosis, angiogenesis, and tumor metastasis. Biomarkers that diagnose, prognose, and guide cancer treatment are crucial, with galectins having the biomarker potential for non-small cell lung cancer (NSCLC). Using enzyme-linked immunosorbent assay (ELISA), we assessed serum galectin-1, -3, and -9 levels in NSCLC patients. A retrospective chart review was performed to examine patient demographics, cancer stage, tumor biology, cancer treatment, and patient outcomes. Galectin levels were then compared across these factors. In this exploratory analysis, galectin-3 levels were significantly lower in patients with squamous cell lung cancer (p = 0.0019) and in patients exposed to chemotherapy (p = 0.0375). Galectin-1 levels were significantly lower in patients with previous metastasis but had no correlation with future metastasis. Abnormal galectin-1 levels were significantly correlated with decreased overall survival (OS) in NSCLC (p = 0.0357) and specifically in patients with surgically resectable NSCLC (p = 0.0112). However, abnormal galectin-1 levels were not found to correlate with decreased OS in multivariable analysis (...
Source: Cancers - Category: Cancer & Oncology Authors: Tags: Article Source Type: research